PARPis, including olaparib (AZD2281, KuDOS/AstraZeneca), niraparib (MK4827, Merck/Tesaro), rucaparib (CO338, AG014699, and PF01367338, Pfizer/Clovis), and veliparib (ABT888, Abbvie), all interact with the binding site of the PARP enzyme cofactor, β-NAD+, in the catalytic domain of PARP1 and PARP2. PARPi have been extensively studied in epithelial ovarian cancers (Table 1) [32,33,34,35,36,37,38,39,40,41,42]. Here, PARP1 is linked to ovarian carcinoma.